Multiple Sklerose und das Altern

In den letzten Jahren konnten Zusammenhänge zwischen dem Altern und Krankheitsmerkmalen von Multipler Sklerose aufgedeckt werden. Zu verstehen, wie das Altern die Pathophysiologie und das Therapieansprechen der Multiplen Sklerose beeinflusst, könnte entscheidend das Outcome der Patienten verbessern.

Liebe Leserin, lieber Leser,

der Inhalt dieses Artikels ist nur für medizinische Fachkreise zugelassen. Wenn Sie zu diesen Fachkreisen gehören, melden Sie sich bitte auf unserer Seite an. Sie werden dann automatisch auf die gewünschte Seite weitergeleitet.

Registrierung Anmeldung Vorteile

Autor:

Dr. Philipp Dworschak (Arzt)

Stand:

13.02.2023

Quelle:

Graves et al. (2023): Ageing and multiple sclerosis. Lancet Neurol. DOI: 10.1016/S1474-4422(22)00184-3
Stankoff et al (2007): Age at onset determines the occurence of the progressive phase of multiple sclerosis. Neurology. DOI: 10.1212/01.wnl.0000256732.36565.4a
Frischer et al. (2015): Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Annals of Neurology. DOI: 10.1002/ana.24497
Marrie et al. (2015): A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview. Multiple Sclerosis Journal. DOI: 10.1177/1352458514564491
Mowry et al. (2018):Body mass index, but not vitamin D status, is associated with brain volume change in MS. Neurology. DOI: 10.1212/WNL.0000000000006644
Salter et al. (2020):. Comorbidity is associated with disease activity in MS: findings from the CombiRx trial. Neurology. DOI: 10.1212/WNL.0000000000010024
Habib et al. (2020): Association between shorter leukocyte telomeres and multiple sclerosis. Journal of Neuroimmunology. DOI: 10.1016/j.jneuroim.2020.577187
Krysko et al. (2019): Telomere length is associated with disability progression in multiple sclerosis. Ann Neurol. DOI: 10.1002/ana.25592
Maggi et al. (2021): Chronic white matter inflammation and serum neurofilament levels in multiple sclerosis. Neurology. DOI: 10.1212/WNL.0000000000012326
Chitnis (2018): The role of testosterone in MS risk and course. Multiple Sclerosis Journal. DOI: 10.1177/1352458517737395
Graves et al. (2018): Ovarian aging is associated with gray matter volume and disability in women with MS. Neurology. DOI: 10.1212/WNL.0000000000004843
Callender et al. (2018): Human CD8+ EMRA T cells display a senescence-associated secretory phenotype regulated by p38 MAPK. Aging Cell . DOI: 10.1111/acel.12675
Huber et al. (2018): An emerging role for eotaxins in neurodegenerative disease. Clinincal Immunology. DOI: 10.1016/j.clim.2016.09.010
Parajuli et al. (2015): CCL11 enhances excitotoxic neuronal death by producing reactive oxygen species in microglia. Glia. DOI: 10.1002/glia.22892
Rothhammer et al. (2018): Microglial control of astrocytes in response to microbial metabolites. Nature. DOI: 10.1038/s41586-018-0119-x
Salazar et al. (2019): Age-associated changes in gut microbiota and dietary components related with the immune system in adulthood and old age: a cross-sectional study. Nutrients. DOI: 10.3390/nu11081765
Franklin, Frisen , Lyons (2021): Revisiting remyelination: towards a consensus on the regeneration of CNS myelin. Seminars in Cell Developmental Biology. DOI: 10.1016/j.semcdb.2020.09.009
Sim et al. (2002): The age-related decrease in CNS remyelination efficiency is attributable to an impairment of both oligodendrocyte progenitor recruitment and differentiation. Journal of Neuroscience. DOI: 10.1523/JNEUROSCI.22-07-02451.2002
Neumann et al. (2019): Metformin restores CNS remyelination capacity by rejuvenating aged stem cells. Cell Stem Cell. DOI: 10.1016/j.stem.2019.08.015
Giorgi et al. (2018): Mitochondria and reactive oxygen species in aging and age-related diseases. International Review of Cell and Molecular Biology. DOI: 10.1016/bs.ircmb.2018.05.006
Barcelos, Troxell, Graves. (2019): Mitochondrial dysfunction and multiple sclerosis. Biology. DO:I 10.3390/biology8020037
Montalban et al. (2017): Ocrelizumab versus placebo in primary progressive multiple sclerosis. The New England Journal of Medicine. DOI: 10.1056/NEJMoa1606468
Kappos et al. (2018): Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. The Lancet. DOI: 10.1016/S0140-6736(18)30475-6
Chataway et al. (2014): Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. The Lancet. DOI: 10.1016/S0140-6736(13)62242-4
Fox et al. (2018): Phase 2 trial of ibudilast in progressive multiple sclerosis. The New England Journal of Medicine.. DOI: 10.1056/NEJMoa1803583